Arca
Skip to content
Tools
Tools

CYSLTR1: Cysteinyl leukotriene receptor 1

Receptor for cysteinyl leukotrienes mediating bronchoconstriction of individuals with and without asthma.

  • Drugs that act on it: 4
  • Approved: 3
  • In phases 1 to 3: 1
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on CYSLTR1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 4

Approved3

  • Montelukast
  • Zafirlukast
  • Pranlukast

Phase 30

    Phase 20

      Phase 11

      • CR-3465 free acid

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Cysteinyl leukotriene receptor 1 antagonist.
      MontelukastBoxed warningApprovedOrganonSmall moleculeAntagonist27
      ZafirlukastApprovedStrides Pharma ScienceSmall moleculeAntagonist1
      PranlukastApprovedOno PharmaceuticalSmall moleculeAntagonist0
      CR-3465 free acidPhase 1—Small moleculeAntagonist0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 9 in all, from ClinicalTrials.gov.
      Evaluating The Role Of Montelukast In Management Of Acute BronchiolitisMontelukastPhase 2RecruitingPakistan Institute of Medical SciencesAug 18, 2026
      MIRACLE-T2D Montelukast Intervention for Renal, Cardiovascular and Eye Health in Type 2 DiabetesMontelukastPhase 4Not yet recruitingUniversity of Colorado, DenverJul 6, 2026
      Effect of Montelukast on Inflammatory Markers and Cardiac Injury in Patients With Acute Myocardial InfarctionMontelukastPhase 2RecruitingOctober 6 UniversityApr 17, 2026
      Comparison of Antihistamine and Antileukotriene Add-On Therapy to Intranasal Corticosteroid in Allergic RhinitisMontelukastPhase 4Not yet recruitingLiaquat National Hospital & Medical CollegeApr 16, 2026
      SMART 2D: Study of Montelukast's Effects on Renal and Cardiovascular Health in Adolescents and Young Adults With Type 2 DiabetesMontelukastEarly phase 1RecruitingUniversity of Colorado, DenverFeb 13, 2026
      Efficacy of Montelukast on STEMl PatientsMontelukastPhase 3RecruitingShanghai Zhongshan HospitalJan 6, 2026
      Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE TrialMontelukastPhase 4RecruitingEmory UniversityAug 3, 2025
      PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary DysplasiaMontelukastPhase 1 / Phase 2RecruitingDuke UniversityAug 3, 2025
      Crossover Study of Zafirlukast in Preventing Allergen-induced Signs and Symptoms in Response to Cat Dander ChallengeZafirlukastPhase 2Not yet recruitingAllergy & Asthma Medical Group & Research CenterOct 5, 2023

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      Asthma
      0.62
      Airway obstruction
      0.53
      Neurodegenerative disease
      0.39
      Parkinson disease
      0.37
      Alzheimer disease
      0.35
      Obstructive sleep apnea syndrome
      0.33
      Lysosomal storage disease
      0.32
      Wheezing
      0.31

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1798, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q9Y271, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.